This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Gallium-68 PSMA
- DrugBank Accession Number
- DB16303
- Background
Not Available
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Structure
Structure for Gallium-68 PSMA (DB16303)
- Weight
- Average: 947.005
Monoisotopic: 946.41714456 - Chemical Formula
- C44H62N6O17
- Synonyms
- Psma-hbed-cc
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Illuccix Kit 25 ug/1 Intravenous Telix Pharmaceuticals (US) Inc. 2021-12-17 Not applicable US 
Locametz Kit 25 ?g Intravenous Novartis Europharm Limited 2023-02-08 Not applicable EU 
Locametz Injection, powder, lyophilized, for solution 25 ug/1 Intravenous Advanced Accelerator Applications Usa, Inc 2022-03-23 Not applicable US
Categories
- Drug Categories
- Not Available
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 9AG41L3AOQ
- CAS number
- 1366302-52-4
- InChI Key
- QJUIUFGOTBRHKP-LQJZCPKCSA-N
- InChI
- InChI=1S/C44H62N6O17/c51-34-13-8-28(22-30(34)24-49(26-40(59)60)20-21-50(27-41(61)62)25-31-23-29(9-14-35(31)52)11-16-38(55)56)10-15-37(54)46-18-4-1-2-7-36(53)45-19-5-3-6-32(42(63)64)47-44(67)48-33(43(65)66)12-17-39(57)58/h8-9,13-14,22-23,32-33,51-52H,1-7,10-12,15-21,24-27H2,(H,45,53)(H,46,54)(H,55,56)(H,57,58)(H,59,60)(H,61,62)(H,63,64)(H,65,66)(H2,47,48,67)/t32-,33-/m0/s1
- IUPAC Name
- (2S)-2-({[(1S)-1-carboxy-5-(6-{3-[3-({[2-({[5-(2-carboxyethyl)-2-hydroxyphenyl]methyl}(carboxymethyl)amino)ethyl](carboxymethyl)amino}methyl)-4-hydroxyphenyl]propanamido}hexanamido)pentyl]carbamoyl}amino)pentanedioic acid
- SMILES
- OC(=O)CC[C@H](NC(=O)N[C@@H](CCCCNC(=O)CCCCCNC(=O)CCC1=CC=C(O)C(CN(CCN(CC(O)=O)CC2=CC(CCC(O)=O)=CC=C2O)CC(O)=O)=C1)C(O)=O)C(O)=O
References
- General References
- Not Available
- External Links
- ChemSpider
- 58827810
- ChEMBL
- CHEMBL3578202
- ZINC
- ZINC000203341463
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Completed Diagnostic Prostate Cancer 1 3 Completed Treatment Castration-Resistant Prostate Carcinoma / Metastatic Carcinoma of the Prostate / Stage IVB Prostate Cancer AJCC v8 1 2 Active Not Recruiting Diagnostic Castration-Resistant Prostate Carcinoma / Metastatic Carcinoma of the Prostate / Stage IV Prostate Cancer AJCC v8 / Stage IVA Prostate Cancer AJCC v8 / Stage IVB Prostate Cancer AJCC v8 1 2 Completed Diagnostic Adenocarcinoma of Prostate / Biochemically Recurrent Prostate Carcinoma / Metastatic Carcinoma of the Prostate / Prostate Carcinoma / PSA Level Greater Than Fifty / PSA Progression / Stage IV Prostate Cancer AJCC v8 / Stage IVA Prostate Cancer AJCC v8 / Stage IVB Prostate Cancer AJCC v8 1 2 Completed Diagnostic Adenocarcinoma of Prostate / Metastatic Prostate Cancer / Prostate Cancer / Recurrent Prostate Cancer 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Kit Intravenous 25 ug/1 Injection, powder, lyophilized, for solution Intravenous 25 ug/1 Kit Intravenous 25 ?g - Prices
- Not Available
- Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region US11027031 No 2021-06-08 2035-07-28 US US11369590 No 2008-08-15 2028-08-15 US
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.059 mg/mL ALOGPS logP 0.41 ALOGPS logP -3.2 Chemaxon logS -4.2 ALOGPS pKa (Strongest Acidic) 0.85 Chemaxon pKa (Strongest Basic) 9.5 Chemaxon Physiological Charge -5 Chemaxon Hydrogen Acceptor Count 19 Chemaxon Hydrogen Donor Count 12 Chemaxon Polar Surface Area 370.07 Å2 Chemaxon Rotatable Bond Count 35 Chemaxon Refractivity 235.64 m3·mol-1 Chemaxon Polarizability 98.3 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at December 15, 2020 18:18 / Updated at January 12, 2022 14:32